Welcome to our dedicated page for Regenerex Pharma SEC filings (Ticker: RGPX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Regenerex Pharma, Inc. (RGPX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Regenerex is an emerging growth company focused on advanced wound closure systems for chronic and acute wounds, and its filings offer insight into corporate structure, reporting practices, and key governance decisions.
Among the notable disclosures, a Form 8-K details the Board of Directors’ decision to change the company’s fiscal year end from March 31 to December 31. This filing explains that the change was made under the authority of the company’s bylaws and notes that a transition report on Form 10-K will cover the period from April 1 to December 31 of the transition year. Such filings help investors understand how Regenerex aligns its reporting calendar with its operational and financial planning.
Regenerex has also filed a Form 12b-25 (Notification of Late Filing) explaining a delay in submitting a Form 10-Q for a specified quarter. In that notification, the company cites unanticipated delays in compiling and reconciling financial data and obtaining information from third-party service providers. The filing states that all other required periodic reports had been submitted and that no significant change in results of operations versus the prior-year period was anticipated.
On this page, users can review these and other SEC documents, including 10-K transition reports, 10-Q quarterly reports, and any future Forms 4 related to insider transactions when they are filed. Stock Titan’s AI-powered tools summarize lengthy filings, highlight key items such as fiscal year changes, reporting delays, and status as an emerging growth company, and make it easier to interpret complex regulatory language without reading every page in detail.
Regenerex Pharma, Inc. reported no revenue for the six months ended September 30, 2025 and a larger net loss of
Regenerex Pharma, Inc. filed a Form 12b-25 to notify a late filing of its Form 10-Q for the quarter ended September 30, 2025. The company explains that it could not complete the quarterly report on time due to unanticipated delays in compiling and reconciling financial data, including additional time needed to obtain and verify information from third-party service providers.
Regenerex states that the Form 10-Q will be filed within the allowed extension period, which for a quarterly report is up to five calendar days after the original due date. The company confirms that all other required periodic reports over the past 12 months have been filed and indicates it does not anticipate any significant change in results of operations compared with the same quarter of the prior year.
Regenerex Pharma (RGPX) changed its fiscal year end to December 31. The Board approved moving the company’s fiscal year end from March 31 to December 31. To bridge the shift, the company will file a transition report on Form 10-K covering the period from April 1, 2025 through December 31, 2025.
This is an administrative change to align reporting periods. The upcoming transition 10-K will provide financials for the nine-month period noted before the new annual cycle begins on a calendar-year basis.
